Clinical study of cefluprenam, a new parenteral cephem antibiotic, in the treatment of complicated urinary tract infection

Keizo Suzuki, Masaki Horiba, Kiyohito Ishikawa, Shinobu Katoh

Research output: Contribution to journalArticlepeer-review

Abstract

Cefluprenam (CFLP), a new injectable cephem antibiotic, was administered in the treatment of 16 cases with chronic complicated UTI and 1 case with acute prostatitis. The results obtained were as follows. Seventeen patients who received the drug were given at a dose of 0.5 g or 1.0 g, twice a day by drip infusion for 5 days. In complicated UTI, 15 patients out of 16 were evaluable by the Japanese UTI criteria, and its assessment was excellent or moderate in all cases treated (efficacy rate: 100%). In 1 case of acute prostatitis the effectiveness was fair. Response against clinical isolates, 25 strains out of 26, that included 16 of gram negative bacilli, 10 of gram positive cocci, were eradicated after treatment. A great potent in vitro activity on such strains as Escherichia coli, Morganella morganii, Proteus mirabilis, was proven as much as ≤0.05 μg/ml of MIC values. So far the clincal data obtained, the relationship between the in vitro study and the clinical one was considered to be detected. In the safety profile, nothing was observed for adverse drug reaction. In laboratory values, in 2 cases, mild transient elevations of S-GOT, S-GPT/S-GOT, SGPT, γ-GTP were noted. Conclusively, CFLP showed a useful strategy for complicated UTI, even though with stubborn UTI caused by Pseudomonas aeruginosa, Enterococcus faecalis. As for safety, no significant differences were observed, compared to the conventional compounds.

Original languageEnglish
Pages (from-to)332-337
Number of pages6
JournalJapanese Journal of Chemotherapy
Volume43
DOIs
Publication statusPublished - 01-01-1995
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Clinical study of cefluprenam, a new parenteral cephem antibiotic, in the treatment of complicated urinary tract infection'. Together they form a unique fingerprint.

Cite this